27 March 2020
COVID-19 measures at Oncode Institute
At Oncode we would like to wish our research community and other stakeholders all the best during these difficult times. With most labs closing down, we fully understand the new situation will have an impact on Oncode related research activities. We are fully focused on creating mitigation plans. We are in close contact with our funders on how to proceed and will provide our researchers with an update once we have more clarity.
27 March 2020
In memoriam: Anjo van Heijst
We received the sad news that Anjo van Heijst passed away on March 23. Anjo was one of the first patient representatives of Oncode’s Clinical Advisory Board. With her knowledge and enthusiasm, she contributed immensely to the development of our clinical programmes. She was also a driving force behind Werkgroep Darmkanker, a platform for patients with colon cancer and their loved ones.
20 March 2020
Two New Clinical Proof-of-Concept Projects Funded by Oncode Institute
Oncode Institute aims to link fundamental and clinical research to enable efficient translation of promising findings into novel diagnostic methods and clinical treatment strategies. We are pleased to announce that the 9th and 10th grant within the Clinical Proof of Concept programme have been awarded.
19 March 2020
Therapeutic vaccine boosts survival rate in cervical cancer patients
A therapeutic vaccine against HPV-16 (type 16 human papillomavirus) improves the survival rate in cervical cancer patients. A new study by Oncode Investigator Sjoerd van der Burg and others shows that this vaccine produces a more robust response if it is combined with chemotherapy. The results of this study have been published in the journal Science Translational Medicine.
17 March 2020
The Oncode Compound Library: find new therapeutic applications that others missed
Oncode’s newly acquired Broad Institute Drug Repurposing Library is now available to all Oncode researchers, through the Drug Repurposing Programme. The library encompasses more than 6.000 unique compounds in different stages of clinical development. Each of them has extensively curated annotations, including details about commercial sources. Besides access to the library, Oncode will provide the technical infrastructure and expertise needed to perform complex compound screens.
Fundamental science, clinical testing and a sharp mind for market opportunities: at Oncode we bring it all together to create impact for patients.
Scroll for more